The interleukin-1 receptor family
- PMID: 24246227
- DOI: 10.1016/j.smim.2013.10.023
The interleukin-1 receptor family
Abstract
The activity of each member of the IL-1 family of ligands is mediated by its own receptor. Each ligand binds specifically to the extracellular "ligand binding chain" containing three Ig-like regions. With the exception of the IL-1 and IL-36 receptor antagonists, a second chain, termed the "accessory chain", is recruited, forms a heterotrimetic complex with the ligand binding chain and the ligand, and signal transduction is initiated. Each ligand binding or accessory chain shares a common cytosolic segment termed the Toll-IL-1-receptor (TIR) domain. Another family of 13 receptors, termed Toll-like receptors (TLR), have extracellular leucine-rich repeat domains, which bind a broad spectrum of microbial products. All TLR share a nearly identical TIR domain with all members of the IL-1 receptor family. Hence signal transduction and the biological consequences of TLR ligands and IL-1 family ligands are often the same and both receptor families contribute to innate inflammation and host defense. The IL-1 family of receptors is comprised of ten distinct but related gene products. The receptors are indicated by the term IL-1 receptor (IL-1R) followed by a numeral, assigned chronologically by discovery, for example, IL-1R1, IL-1R2, IL-1R3, etc. The ligand binding chain for IL-1α and IL-1β is IL-1R1 and the accessory chain is IL-1R3. IL-1α, IL-1β, IL-33 and IL-36 use IL-1R3 as their accessory chain. IL-1R2 is a non-signalling "decoy" receptor that sequesters the IL-1β and IL-1R3. IL-1R8 exhibits anti-inflammatory properties by reducing IL-1 and TLR signalling. Presently there are two orphan receptors, IL-1R9 and IL-1R10, which have no known function. This review examines the characteristics and functional roles of the IL-1R family in the regulation of innate inflammation, host defense and acquired immunity.
Keywords: IL-1 receptors; IL-1R family; Inflammation; Interleukin-1; Resolution.
Copyright © 2013 Elsevier Ltd. All rights reserved.
Similar articles
-
Overview of the interleukin-1 family of ligands and receptors.Semin Immunol. 2013 Dec 15;25(6):389-93. doi: 10.1016/j.smim.2013.10.001. Epub 2013 Nov 23. Semin Immunol. 2013. PMID: 24275600
-
The family of the interleukin-1 receptors.Immunol Rev. 2018 Jan;281(1):197-232. doi: 10.1111/imr.12606. Immunol Rev. 2018. PMID: 29248002 Review.
-
The interleukin-1 receptor family.Vitam Horm. 2006;74:229-54. doi: 10.1016/S0083-6729(06)74009-2. Vitam Horm. 2006. PMID: 17027517 Review.
-
The interleukin-1 receptor/Toll-like receptor superfamily: signal transduction during inflammation and host defense.Sci STKE. 2003 Feb 25;2003(171):re3. doi: 10.1126/stke.2003.171.re3. Sci STKE. 2003. PMID: 12606705 Review.
-
TIR8/SIGIRR: an IL-1R/TLR family member with regulatory functions in inflammation and T cell polarization.Trends Immunol. 2009 Sep;30(9):439-46. doi: 10.1016/j.it.2009.06.001. Epub 2009 Aug 21. Trends Immunol. 2009. PMID: 19699681 Review.
Cited by
-
MyD88-Dependent Signaling Decreases the Antitumor Efficacy of Epidermal Growth Factor Receptor Inhibition in Head and Neck Cancer Cells.Cancer Res. 2015 Apr 15;75(8):1657-67. doi: 10.1158/0008-5472.CAN-14-2061. Epub 2015 Feb 20. Cancer Res. 2015. PMID: 25712126 Free PMC article.
-
Platelet-Rich Plasma and Cartilage Repair.Curr Rev Musculoskelet Med. 2018 Dec;11(4):573-582. doi: 10.1007/s12178-018-9516-x. Curr Rev Musculoskelet Med. 2018. PMID: 30203333 Free PMC article. Review.
-
Recent advance in treatment of atherosclerosis: Key targets and plaque-positioned delivery strategies.J Tissue Eng. 2022 Mar 24;13:20417314221088509. doi: 10.1177/20417314221088509. eCollection 2022 Jan-Dec. J Tissue Eng. 2022. PMID: 35356091 Free PMC article. Review.
-
A natural bioactive feed additive alters expression of genes involved in inflammation in whole blood of healthy Angus heifers.Innate Immun. 2020 May;26(4):285-293. doi: 10.1177/1753425919887232. Epub 2019 Nov 19. Innate Immun. 2020. PMID: 31744342 Free PMC article.
-
Interleukin-38 and Insulin Resistance.Endocr Metab Immune Disord Drug Targets. 2024;24(6):611-616. doi: 10.2174/1871530323666230911114150. Endocr Metab Immune Disord Drug Targets. 2024. PMID: 37702180
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous